Single ascending dose results from a Phase 1 clinical trial of BT-600, a combination product of the NaviCap™ targeted oral delivery platform and tofacitinib

A Phase 1, randomized, double-blind, placebo-controlled, sequential, single and multiple ascending dose (SAD/MAD) clinical trial evaluated the safety and pharmacokinetics of BT-600 in healthy adult participants.

Despite approved treatments for UC, outcomes remain sub-optimal with clinical remission rates after induction ranging from 15–30%,¹ and 60% of patients who achieve remission relapse within 12 months.² Data for JAK-inhibitors, TNF-inhibitors, and anti-integrins demonstrate that achieving higher drug levels and activity in colon tissue mucosa could improve clinical benefit.^3,4,5 Higher doses of systemic treatments or combination treatments may be needed to achieve sufficient colonic tissue exposure but are limited by systemic safety risks.^6,7

BT-600 is an ingestible drug/device combination product designed for targeted delivery of a liquid formulation of tofacitinib into the colon and has potential for improved efficacy driven by increased colonic tissue exposure, while reducing systemic-exposure-associated adverse events. BT-600 utilizes the NaviCap™ device, designed to deliver a liquid drug formulation directly to the colon mucosa, bypassing the upper gastrointestinal (GI) tract. The NaviCap™ platform is distinct in its ability to precisely target and coat the entire colon with a liquid formulation of therapeutic.

A pre-specified interim analysis included results on safety, plasma PK, and evidence of drug in feces during the SAD portion, and is presented in this poster, along with a summary of results from the MAD portion of the study.

This abstract was awarded a Presidential Poster Award by the ACG Abstract Selection Committee for high quality, novel, unique, and interesting research. Each year less than 5% of accepted abstracts receive this distinction. 

REFERENCES

1. Hirten RP, Sands BE. New therapeutics for ulcerative colitis. Annu Rev Med. 2021 Jan 27;72:199–213.
2. Fumery M, Sing S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: A systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343-356.e3.
3. Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249-255.
4. Pauwels RWM, Proietti E, van der Woude CJ, et al. Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(11):1813-1820.
5. Verstockt B, Alsoud D, van Oostrom J, et al. Tofacitinib tissue exposure correlates with endoscopic outcome. Poster presented at: 17th Congress of the European Crohn’s and Colitis Organisation (ECCO), February 18, 2022, virtual.
6. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616-24.
7. Rubin DT, Motoya S, Schreiber S. Tofacitinib 15 milligrams twice daily for patients with moderate to severe ulcerative colitis: results from 8-Week induction studies OCTAVE induction 1 & 2. Am J Gastroenterol. 2018; 113:S403.
8. Feagan B, Razag G, Lee SN, et al. Single ascending dose results from a Phase 1 clinical trial of BT-600, a combination product of the NaviCap targeted oral delivery platform and tofacitinib. Poster presented at the American College of Gastroenterology Annual Scientific Meeting, October 25–30, 2024, Philadelphia, Pennsylvania.